Zoetis Inc. (NYSE:ZTS)’s dermatology franchise, including Apoquel, has also seen significant success, growing from a $70 million to a $1.5 billion market, making Apoquel the top prescribed ...
Hosted on MSN11mon
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?Zoetis, Inc. ZTS is anticipated to beat estimates when it reports its fourth-quarter and full-year 2023 results on Feb 13, before market open. Zoetis has an encouraging surprise history so far.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results